Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 5/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.37 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.33 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL440141 | 0.98 | OPRM1 (0.50) | OPRM1POLBSLC6A4SLC6A2SLC6A3 | |
| SCHEMBL23411132 | 0.98 | OPRM1 (0.50) | OPRM1POLBSLC6A4SLC6A2SLC6A3 | |
| SCHEMBL23727554 | 0.82 | OPRM1 (0.40) | OPRM1SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL10477634 | 0.82 | SMN1; SMN2 (0.40) | OPRM1POLBSLC6A4MEN1ALOX15 | |
| SCHEMBL3181237 | 0.82 | SMN1; SMN2 (0.44) | OPRM1POLBSLC6A4KDM4EMEN1 | |
| SCHEMBL25388316 | 0.81 | OPRM1 (0.40) | OPRM1SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL31277004 | 0.80 | ALDH1A1 (0.37) | OPRM1POLBSLC6A4MEN1ALOX15 | |
| SCHEMBL10477609 | 0.80 | SMN1; SMN2 (0.39) | OPRM1POLBSLC6A4KDM4EMEN1 | |
| SCHEMBL16058884 | 0.80 | SMN1; SMN2 (0.39) | OPRM1POLBSLC6A4MEN1ALOX15 | |
| SCHEMBL2814112 | 0.80 | OPRM1 (0.54) | OPRM1POLBSLC6A4SLC6A2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 189 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026098560-A2 | BENZENE-CONTAINING POLYCYCLIC DERIVATIVE MODULATOR, PREPARATION METHOD THEREFOR AND USE THEREOF | 上海翰森生物医药科技有限公司 | 2026-05-15 | — | — | WO | disclosed |
| US-12624003-B2 | Carboxylic acid containing indanyl compounds for the treatment of neurodegenerative diseases | CELGENE CORPORATION (US) | 2026-05-12 | — | — | US | disclosed |
| WO-2026087442-A1 | AMINO-IMIDAZOLE ANTIBACTERIAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2026-04-30 | — | — | WO | disclosed |
| EP-4267117-B1 | CARBOXYLIC ACID CONTAINING INDANYL COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | CELGENE CORP (US) | 2026-04-08 | — | — | EP | disclosed |
| US-20250179032-A1 | HETEROCYCLIC INHIBITORS OF GLUT9 FOR TREATMENT OF DISEASE | HORIZON THERAPEUTICS IRELAND DAC (IE) | 2025-06-05 | — | — | US | disclosed |
| EP-4553068-A1 | PYRIMIDINE DERIVATIVES | ASKA Pharmaceutical Co., Ltd. (JP) | 2025-05-14 | — | — | EP | disclosed |
| US-20250026721-A1 | COMPOUNDS AND METHODS FOR MODULATING RAS-PI3K | VIVIDION THERAPEUTICS, INC. | 2025-01-23 | — | — | US | disclosed |
| US-20250026749-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORPORATION (US) | 2025-01-23 | — | — | US | disclosed |
| CN-119285572-A | Kinase inhibitors and uses thereof | 戴纳立制药公司 | 2025-01-10 | — | — | CN | disclosed |
| US-20250011338-A1 | Kinase Inhibitors and Uses Thereof | DENALI THERAPEUTICS INC. (US) | 2025-01-09 | — | — | US | disclosed |
| US-20080119487-A1 | NOVEL NON-IMIDAZOLE COMPOUNDS | SCHERING CORPORATION | 2008-05-22 | — | — | US | disclosed |
| US-7300941-B2 | Non-imidazole compounds | SCHERING CORPORATION (US) | 2007-11-27 | — | — | US | disclosed |
| US-7300941-B2 | Non-imidazole compounds | SCHERING CORPORATION (US) | 2007-11-27 | — | — | US | disclosed |
| EP-1777223-A1 | Indole derivatives useful as histamine H3 antagonists | SCHERING CORPORATION (US) | 2007-04-25 | — | — | EP | disclosed |
| EP-1539742-B1 | INDOLE DERIVATIVES USEFUL AS HISTAMINE H3 ANTAGONISTS | SCHERING CORP (US) | 2006-11-08 | — | — | EP | disclosed |
| US-6951871-B2 | Indole derivatives useful as histamine H3 antagonists | SCHERING CORPORATION (US) | 2005-10-04 | — | — | US | disclosed |
| EP-1539742-A1 | INDOLE DERIVATIVES USEFUL AS HISTAMINE H3 ANTAGONISTS | SCHERING CORPORATION (US) | 2005-06-15 | — | — | EP | disclosed |
| WO-2005016883-A2 | ACRYLAMIDE DERIVATIVES AS VLA-1 INTEGRIN ANTAGONISTS AND USES THEREOF | ICOS CORPORATION (US) | 2005-02-24 | — | — | WO | disclosed |
| US-20040019099-A1 | Treating inflammatory diseases, allergic conditions and central nervous system disorders | SCHERING CORPORATION | 2004-01-29 | — | — | US | disclosed |
| WO-2004000831-A1 | INDOLE DERIVATIVES USEFUL AS HISTAMINE H3 ANTAGONISTS | SCHERING CORPORATION (US) | 2003-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250011338-A1 | Kinase Inhibitors and Uses Thereof | MAP3K20, MAP3K6, MAP3K19 | OPRM1 3889/4885POLB 968/4885SLC6A4 4769/4885 |
| US-20250026721-A1 | COMPOUNDS AND METHODS FOR MODULATING RAS-PI3K | KRAS, HRAS, NRAS | OPRM1 4203/4885POLB 3197/4885SLC6A4 4326/4885 |
| US-20250179032-A1 | HETEROCYCLIC INHIBITORS OF GLUT9 FOR TREATMENT OF DISEASE | SLC2A9, SLC2A1, SLC2A8 | OPRM1 4560/4885POLB 4712/4885SLC6A4 311/4885 |
| US-20250026749-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GBA1, GBA2, GAA | OPRM1 4772/4885POLB 1543/4885SLC6A4 3917/4885 |
| US-12624003-B2 | Carboxylic acid containing indanyl compounds for the treatment of neurodegenerative diseases | S1PR5, LPAR5, S1PR2 | OPRM1 790/4885POLB 4011/4885SLC6A4 652/4885 |
| US-20040019099-A1 | Treating inflammatory diseases, allergic conditions and central nervous system disorders | HRH2, HRH4, HRH1 | OPRM1 110/4885POLB 4196/4885SLC6A4 2485/4885 |
| US-20080119487-A1 | NOVEL NON-IMIDAZOLE COMPOUNDS | HRH2, HRH1, HRH4 | OPRM1 571/4885POLB 3869/4885SLC6A4 3338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.